An interventional study of HIVE Mobile Health Application and HIVE Interpersonal Support (IPS) in Implementation of Integrated Care for People Living With HIV and Multiple Long-Term Conditions, sponsored by University of Nicosia. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of Nicosia · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The rising burden of non-communicable diseases (NCDs) among people living with HIV (PLWH) poses significant challenges to healthcare systems. Addressing this dual disease burden requires a transition from vertical, disease-specific programs to comprehensive patient-centered integrated chronic care models. However, resource constraints, fragmented service delivery, and limited patient engagement impede progress. Mobile health (mHealth) interventions have emerged as a promising strategy to enhance self-management, foster peer support, and improve patient engagement in the context of HIV-NCD multimorbidity.
The pre-post interventional trial aims to evaluate the HIVE interventions framework in the management of long-term conditions such as non-communicable diseases and mental health conditions, among PLWH. The HIVE interventions comprise a mobile health application (HIVE App), tools that enhance integrated NCD care management and interpersonal support. Up to 260 PLWH will be enrolled from clinical sites from four countries: Greece, Kazakhstan, Kenya and Malta. Following the baseline visit, they will be followed for one year with 3 follow-up visits every four months. The primary outcome of interest is a significant improvement in self-management capability among PLWH with at least one NCD, as measured by the Appraisal of Self-Care Agency Scale-Revised (ASAS-R) scores. Secondary outcomes include the significant improvement in self-efficacy for managing medications and symptoms of chronic conditions (PROMIS), Health-related Quality of Life (HRQOL), awareness of NCD and mental health assessment scores (GAD-7 and PHQ-9).
This HIVE trial also incorporates evaluation of the implementation processes and implementation outcomes of the HIVE interventions. The Nonadoption, Abandonment, Scale-up, Spread and Sustainability (NASSS) framework will guide the assessment of barriers and facilitators of the HIVE interventions, with particular focus on adoption, engagement and acceptability, cost-effectiveness analysis and social impact analysis. NASSS domains will be evaluated through a survey and at least two focus group discussions with participants from all four sites. Additionally, semi-structured interviews will be held with healthcare professionals at the sites to explore their perspectives on the patients' adoption and acceptability to the HIVE interventions, as well as their perspectives on the integration of the implementation framework in NCD care.
HIVE's core concept revolves around three essential interventions:
People with HIV and NCDs represent a population with complex, long-term care needs that require sustained engagement across multiple levels of the health system. Therefore, a subsequent implementation framework evaluation is warranted to assess the feasibility, acceptability, and contextual factors influencing adoption, integration, and sustainability of the intervention in real-world settings. This second phase of this protocol will examine implementation outcomes from the perspectives of end users and healthcare providers, allowing identification of facilitators and barriers to delivery of the mHealth intervention within HIV and chronic disease care pathways. Findings from this implementation evaluation will inform optimization of the intervention, guide future scale-up, and enhance the potential for sustained impact beyond the trial setting.
HYPOTHESIS We hypothesize the HIVE intervention will result in a 50% sustained increase in patients' self-management capability of their multiple long-term conditions.
Study Objectives and Endpoints Primary Objective The primary objective of the HIVE trial is to evaluate the effectiveness of the HIVE intervention in improving self-management efficacy among people living with HIV (PLWH) who have at least one non-communicable disease (NCD). This will be assessed by measuring the change in Appraisal of Self-Care Agency Scale-Revised (ASAS-R) scores from baseline to month 12.
Secondary Objectives
The secondary objectives of the HIVE trial are as follows:
METHODOLOGY 6.1 Study Site A total of 5 clinical sites across four countries (Greece, Kazakhstan, Kenya and Malta) are going to contribute to the recruitment of the study population. The sites are described below.
Greece The First Department of Internal Medicine and the Pathophysiology Department of the National and Kapodistrian University of Athens (NKUA) are two prominent HIV outpatient and inpatient clinics within one of the largest hospitals in Athens, Greece. Together, they provide care to over 1,300 people living with HIV (PLWH), forming well-established patient cohorts that support efficient recruitment for clinical trials.
Both departments have an extensive track record in clinical and scientific research, with a particular focus on the comprehensive, holistic management of PLWH. Their longstanding experience enhances their ability to coordinate and conduct high-quality clinical studies. They offer the necessary infrastructure, academic expertise, and administrative support to ensure the successful implementation of research projects, creating a resource-rich environment that fosters excellence in HIV research.
Kazakhstan Almaty city AIDS center is a health care facility that is focused on providing HIV treatment and care for PLHIV, including antiretroviral therapy (ART), testing on hepatitis, STIs, tuberculosis. All PLHIV registered in Almaty have access to HIV treatment and care covered by the health insurance of the country. As of April 1, 2025, 4,952 people are receiving ART, representing 98% of all registered people living with HIV in Almaty, 1095 have history of injection drug use and 455 ever self-reported alcohol addiction. Almaty city AIDS center is also responsible for the development and implementation of HIV prevention programs at all levels in Almaty. The center has an Extensive HIV Testing Network. Testing is accessible for all population groups, including key populations, through the primary health care (PHC) system. The center also provides pre-and post- exposure prophylaxis. The Center is instrumental in deploying innovative strategies such as social network testing (peer-referral testing), home-based care for patients with unsuppressed viral load, and self-testing distribution platforms (HIVTEST.KZ). In the 1st quarter of 2025, 149,000 HIV tests were conducted. In research contexts, the Almaty City AIDS Center serves as a referral site and data source for scholarly studies.
Kenya Kombewa Clinical Research Center The Kombewa Clinical Research Center (KCRC) is a research site formed through a collaboration between the Walter Reed Army Institute of Research- Africa (WRAIR-A) and Kenya Medical Research Institute (KEMRI). It is located in the Western Kenya Field Station in Kisumu County. The Western Kenya Field Station conducts a wide spectrum of field and laboratory work including numerous clinical research trials, malaria drug resistance studies, entomology studies, basic science research studies, malaria diagnostic studies and trainings, surveillance through the Kombewa Health and Demographic Surveillance System and the Department of Emerging Infectious Diseases (DEID) and HIV studies, care and treatment program through the Kisumu West PEPFAR program (in collaboration with the Kenyan Ministry of Health as the implementing partner for HIV care and treatment). It is well designed for large clinical trials and has a full clinical laboratory, including microbiology capability. Studies conducted cover different scientific areas, including epidemiology and surveillance (field-based and clinic-based), entomology, basic immunology, clinic-based vaccine and therapeutic trials, hospital-based treatment trials and community-based studies of drugs. KCRC is located opposite the Kombewa County Referral Hospital, which serves as a HIV comprehensive care center. The research team has a close affiliation with the Kenya Ministry of Health at the county and national levels and with the personnel working in the Ministry of Health facilities within the study area. Trained KEMRI/WRAIR-A Field Officers and Ministry of Health Community Health Workers assist with study activities conducted in the field and in satellite facilities.
Center for Family Health Research and Development (CEFERD):
The CEFERD site is based at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), a level-6 hospital serving the population of Western Kenya. It is the main referral center to 10 counties in western Kenya and rift valley with a population of more than 7 million people. The hospital has a bed capacity of 830. JOOTRH has one of the largest HIV clinics, which currently supports 6,820 patients living with HIV (PLHIV) on HAART. A substantial proportion of these PLHIV also have non-communicable diseases (NCDs), including hypertension (769), diabetes (138), and mental health disorders (20) among PLHIVs.
In both Kombewa and JOOTRH, HIV management follows the national ART guidelines which recommend ART initiation at diagnosis "irrespective of CD4 cell count or percentage, WHO clinical stage, age, pregnancy status, or comorbidities". Additionally, the guidelines recommend annual screening for hypertension, diabetes mellitus, dyslipidaemia, mental health conditions, and renal disease. Routine screening for early detection of cervical cancer, breast cancer, bowel cancer, and prostate cancer is also recommended. The Ministry of Health promotes the use of digital health solutions to support HIV care. Nishauri, a commercially available mHealth app has been used to support HIV care in Kenya. Nishauri functions include provider and patient access to medical records, direct (provider-patient) and mass messaging, scheduling ART transfers, clinic visit appointments and reminders. Adoption and utilization of Nishauri varies by clinic, provider, and patients, which may influence effectiveness of Nishauri on HIV care outcomes. The app integrates with systems like Kenya Electronic Medical Records (KenyaEMR) and the Ushauri platform to facilitate data exchange between healthcare facilities, enabling continuity of care during patient transfers.
Malta Mater Dei Hospital is the only acute general teaching hospital in Malta that is run by the Ministry for Health \& Active Ageing. The hospital aims to create a centre of excellence in the provision of effective and efficient patient-centred quality care, both in the acute and in the chronic setting. With regards to the HIV clinic at Mater Dei Hospital, it offers the unique advantage that it is the sole clinic for subjects with HIV in the Maltese archipelago. Hence, patients are not lost to follow-up. In addition, they are very easily traceable. Another important aspect of the clinic is that a variety of other specialists are readily available. These include, amongst others, diabetologists, cardiologists, nephrologists, neurologists as well as psychiatrists and psychologists, thus ensuring that the patients attending the clinic are provided by the best possible holistic approach in an efficient manner. The clinic also offers highly professional nursing staff who have a close and supportive relationship with all the patients. With regards to HIV management, the European Aids Clinical Society (EACS) guidelines are followed. These guidelines ensure easily accessible and comprehensive recommendations to clinicians involved in all aspects of care.
Study Design: HIVE Trial The HIVE Trial will be conducted in two parts. An initial formative phase to help streamline the tools and implementation processes. A small number (about 3-5 per site) will be recruited for this phase. Following informed consent and screening processes, if eligible will be offered the HIVE interventions and followed up for up to 2 weeks. During this period, enrollment will be temporarily paused. Data collected during this period will be used to update study tools and study processes as needed. These initial participants will proceed with the trial per the schedule of activities.
Enrollment will then resume for the second part. For the second part of the HIVE Trial, the remaining participants will be recruited to achieve the target sample size. More details about the trial are outlined below:
This is a single arm clinical trial. Study design: "Pre-post" Prospective study Allocation: Single group assignment.
Interventions: The HIVE Trial interventions comprise:
Recruitment period: 4 months Trial Up period: 12 months Follow-Up Intervals: 4 months (Data collection points are: Visit 1; baseline, Visit 2; at month 4, Visit 3 at month 8 and Visit 4 at month 12)
Study Design: Implementation Framework Evaluation A mixed-methods, multi-site implementation evaluation design will be employed to assess the adoption, penetration, and acceptability of the HIVE interventions across four pilot sites. The study is grounded in a triangulation approach, integrating quantitative and qualitative data collected from multiple stakeholder groups. Quantitative survey data will be combined with qualitative data from focus groups and semi-structured interviews to provide a comprehensive understanding of user engagement and implementation outcomes. A common methodological framework will be applied across all pilot sites to ensure comparability of findings.
The implementation evaluation is informed by the NASSS framework to examine complexity across organisational, technological, and contextual domains, while COM-B is used to explore behavioural determinants influencing intervention uptake and engagement. Process evaluation domains adapted from Steckler and Linnan guide the assessment of fidelity, reach, dose delivered, dose received, recruitment, and contextual influences Implementation outcomes will be assessed through triangulation of quantitative implementation indicators (e.g., uptake, retention, adherence, app engagement metrics) and qualitative process data collected through semi-structured interviews, focus groups, implementation logs, and reflective site-level documentation.
Social Impact Analysis A Social Network Analysis (SNA) will be conducted to examine the interpersonal relationships, information-sharing patterns, and support networks that develop among patients participating in the HIVE clinical trial across all four pilot sites. This coherent method involves administering SNA surveys to enrolled patients to capture the structure and strength of their peer interactions, including whom they seek for advice, emotional support, or practical guidance related to managing HIV and comorbid NCDs. Mapping these patient networks will enable the study team to assess key structural features, such as centrality, clustering, cohesion, and the presence of informal peer leaders, and to understand how social connectedness influences engagement with the HIVE interventions. Data collection for the SNA will rely on a structured survey with closed-ended questions through which patients will report their interactions, support exchanges, and communication preferences within the trial.
To deepen the interpretation of the quantitative network structures identified through the SNA, semi-structured interviews will be conducted with end-users of the HIVE Application and healthcare professionals who interact closely with patients throughout the trial process. These interviews will explore how clinical routines, communication practices, and site-level organisational factors shape the emergence, strength, and sustainability of patient-to-patient networks. Stakeholders will provide insight into observed patterns, such as why certain patients become informal peer nodes, how trust and information flow are influenced by clinical interactions, and what contextual barriers or facilitators affect peer engagement. By integrating SNA metrics with these qualitative perspectives, the study will generate a more comprehensive understanding of how patient networks operate within the trial environment and how they influence the adoption, engagement, and overall implementation of the HIVE interventions across sites.
Study Intervention: HIVE Trial The HIVE trial comprises three interventions: a mobile health application, interpersonal support and tools to enhance integration of NCD care into HIV clinics.
HIVE Mobile Application
The HIVE mhealth application will be adapted from an existing application called REACH4Health. REACH4Health was developed by health education professionals of the Center for Sustainable Development (CSD) at Columbia University (CSD), its academic and civil society partners and youth, with a co-design approach. REACH4Health was developed to improve young people's health literacy and health care access via digital technologies in certain countries affected by forced migration. The app enables access to reliable information on Physical Health, Mental Health, Social Health, Healthy Lifestyle Behaviors and Health Promotion, Environmental Health, Healthcare System, Health-related Laws, Rights and Health Insurance, and COVID-19 with links to international and local institutional websites. Current features are outlined below:
Health topics: plain-language content on physical/mental health, lifestyles, COVID-19 Service locator: map to nearby hospitals, clinics, and health centers Health system navigation: guidance on how local systems work, patient rights, insurance Expert connection: chat/connection to a health mediator for questions and support Multi-language support (e.g., English, Arabic, Turkish) The HIVE Project aims to perform the necessary adaptation and extensions to the existing App to develop the HIVE application. This includes redesigning the user interface to render it more user-friendly and intuitive, enriching the content to match the needs of the users, adding features not available in its current version as described in the methodology, ensuring compatibility with the latest versions of operating systems, including more languages and integrating AI technology to deliver smart wellness recommendations and increased usability. This will largely be informed by the results from research activities from part 1 of the HIVE Project; HIV population health needs assessment.
The integration of features coordinates with the co-creation workshops to achieve rapid development and delivery in an iterative manner; User needs, requirements, and feedback collected during each co-creation workshop will be translated into prioritized functional specifications and incorporated into short development cycles. Each cycle includes design, implementation, internal testing, and validation with stakeholders, allowing for rapid refinement of features based on real-world input.
HIVE App Features:
Medication support: regimen reminders (pills/appointments) Medication lexicon: drug interactions and side effects Health companion: personal health diary to track symptoms, habits, and goals Health Literacy: curated resources (articles and/or videos) for HIV + common NCDs AI-powered assistance: personalized, non-clinical nudges, smart reminders, motivational feedback, and improved search (there will be no diagnosis or treatment recommendations) Interpersonal Support Interpersonal Support (IPS) refers to a structured, person-centred psychosocial approach that aims to support individuals in addressing interpersonal difficulties, strengthening social support, improving coping strategies, and enhancing engagement with care. Within the HIVE trial, IPS will be adapted to the context of people living with HIV and co-existing NCDs, with attention to issues such as stigma, chronic illness self-management, treatment engagement, and barriers to accessing care. IPS is not intended to replace specialist psychiatric care, psychotherapy, or counselling where these are clinically indicated. A cultural adaptation of interpersonal support delivery will be carried out and contextualised to the HIV population. This will be accomplished through literature review, focus groups discussions and utilisation of cultural adaptation frameworks.
A literature review on the delivery of interpersonal support to PLWH will be performed. This will aim to identify the impact of interpersonal support on PLWH, the different cultures in which it has been delivered to PLWH and whether any differences were observed between cultures.
The following three cultural adaptation frameworks will be used: Assessment, Decision, Adaptation, Production, Topical experts-integration, Training, and Testing (ADAPT-ITT), Ecological Validity Framework (EVF) and Psychotherapy Adaptation and Modification Framework (PAMF). These frameworks will guide the development of a culturally adapted interpersonal support manual.
Moreover, data will be collected from the focus groups held with PLWH as well as health care professionals. Focus group discussions will indicate what the patients' mental health needs are, which challenges they face (e.g., stigma, gender-based violence, lack of support) and cultural issues. Health care professionals from the research team, across all clinical sites, will also provide their input to help refine the manual to enhance its contextual relevance and cultural sensitivity. Their input with regard to cultural adaptation of interpersonal support will be sought. This will help guide the trained providers when delivering this intervention.
Each clinical site will identify and recruit trained providers who should ideally be psychologists or counsellors. If these professionals are not available, it can be delivered by nurses, social workers or community health providers, depending on the individual clinical sites' resources.
The training for identified individuals will be provided. The Association of Psychological Therapists (APT) delivers a three-day training in interpersonal therapy. Training incorporates workbooks, online resources and certification. Additionally, staff will participate in workshops on stigma reduction, gender-sensitive approaches and inclusive care. These workshops should ideally be led by psychiatrists or psychologists or professionals with experience in gender-sensitive approaches and inclusive care virtually.
Professionals will then receive training on the culturally adapted interpersonal support manual. This will take into account use of non-stigmatizing language, HIV-relevant interpersonal scenarios and alignment of therapy goals with cultural norms around family, responsibility and community.
All PLWH entering the trial will be offered IPS at baseline and those who consent will receive around 6-8 sessions of interpersonal support on a weekly or fortnightly basis. For those who decline IPS at baseline, it will be offered again during the first follow-up visit at month 4. Exact number of sessions is at the discretion of the trained professional, with more sessions being offered to those patients who may require them.
The sessions should ideally be delivered face-to-face to allow for development of therapeutic rapport and improved communication, especially the discussion of sensitive topics. However, if this is not possible sessions may be delivered virtually. At least two IPS sessions will be delivered virtually.
Interpersonal support delivery and its impact on PLWH's mental health will be evaluated via pre- and post-therapy questionnaires, namely the Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder-7 (GAD-7) and World Health Organisation Quality of Life (WHOQOL-HIV BREF).
The results of all 5 clinical sites will be evaluated to assess if there are differences in response amongst different cultures.
Integration of NCD Care into HIV clinics Non-communicable disease (NCD) care refers to the prevention, screening, diagnosis, treatment, monitoring, and long-term management of chronic conditions that are not transmitted from person to person. For this study, the NCDs of interest are hypertension, diabetes mellitus, dyslipidaemia, ischemic heart disease, heart failure , lung-, colon-, breast-, cervical-, anal cancers, Kaposi's sarcoma, lymphoma, depression and anxiety disorder . In the context of HIVE, NCD care includes routine assessment of NCD risk factors, identification of existing comorbidities, support for treatment adherence and lifestyle modification, patient education, referral to appropriate specialist services when needed, and coordination of NCD management within HIV care.
An extensive review of the existing WHO and national guidelines for NCD management in relation to HIV will be conducted. This will take into account the incidence of the major NCDs in the countries included in the consortium (Greece, Kenya, Kazakhstan and Malta) with a focus on: diabetes mellitus, hypertension, dyslipidaemia, ischaemic heart disease, heart failure, lung-, colon-, breast-, cervical-, and anal cancers, Kaposi's sarcoma and lymphomas. This will assist in the development of tools that will enhance integrated NCD care as regards screening, treatment and monitoring. These tools will be modified to account for the unique health needs and risks of the target populations and the healthcare system capacity and gaps of each setting. Consequently, training programs and materials will be prepared for healthcare providers, focusing on NCD prevention, diagnosis and basic treatment in the HIV context. All training materials are adapted to the healthcare systems, needs and culture of each site. Training programs will include webinars with short assessment questions at the end of each webinar. A certificate will be provided to healthcare professionals that complete the full training programme. Healthcare professionals will also be asked to evaluate the training programme.
The knowledge of PLWH in relation to NCDs in various healthcare settings will be assessed via a questionnaire that will be distributed amongst subjects enrolled in the HIVE trial in the various institutions. The questionnaire will assess the participant's awareness and knowledge with regards to NCDs as well as determine the participant's satisfaction with regards to NCD management. Consequently, the HIVE participants will be provided with educational material that is also adapted to the needs and culture of each site. Such educational material will be delivered to the patients through the HIVE mobile application. At the end of the HIVE trial, participants will be asked to complete once again the questionnaire, to determine any improvement in patient's empowerment in NCD management following use of the HIVE mhealth application.
Procedures Study Procedures: HIVE Trial The trial will be conducted in two sequential phases: a formative phase followed by the main implementation phase. The formative phase is designed to refine study instruments and optimize operational procedures prior to full-scale enrollment. Approximately 3-5 participants per site will be enrolled during this phase. Following provision of written informed consent and completion of screening procedures, participants who meet eligibility criteria will be initiated on the HIVE intervention and followed for up to 14 days. Enrollment into the study will be paused during completion of the formative phase to allow for evaluation of processes.
Data generated during this period will be systematically reviewed to inform modifications to study tools, data collection instruments, and implementation procedures, as appropriate. Participants enrolled in the formative phase will not be excluded from further participation and will continue in the study in accordance with the full protocol-defined Schedule of Activities.
Enrollment will then resume for the second part. For the second part of the HIVE Trial, the remaining participants will be recruited to achieve the target sample size. More details about the trial are outlined below.
The study design includes one baseline inclusion visit to check the study eligibility criteria, inform about the study, sign written informed consent and perform the study procedures. Once the participant is enrolled in the study, there is a 12-month period with 4-month follow-up intervals for the assessment of the process of the planned interventions. Clinical and sociodemographic data will be collected for each participant at baseline. The recruitment period will be 4 months. The planned interventions specifically include:
Sociodemographic information: Age, gender, educational level, occupation. HIVE application: Each patient will be required to download and install the app on their smartphone or tablet, which will provide direct access to the integrated long-term condition management.
Clinical Examination: Medical history assessment, measurement of weight and height, vital signs (pulse rate, blood pressure, respiratory rate) and routine physical examination.
Standard-of-care follow-up examinations: Before the initiation of the trial, the clinical partners will discuss and agree on a commonly accepted standard-of-care follow-up plan according to the current national and international medical guidelines.
Questionnaires: The Appraisal of Self-care Agency Scale Revised, PROMIS tools for Self-Efficacy for Managing Medications and Treatments and for Managing Symptoms of chronic conditions, Awareness of NCD Questionnaires and the World Health Organization to assess health-related quality of life in adults living with HIV (WHOQOL-HIV BREF). Additional validated patient reported outcomes include the PHQ-9 and GAD-7 tools. Finally, the Mobile Application Rating Scale: user version (uMARS) will be used for the assessment of the HIVE app's user acceptance and usability.
Interpersonal Support Sessions: Six to eight in-person or virtual sessions will be administered for each participant. At least 2 sessions will be delivered virtually.
Each enrolled patient is going to participate for a total of twelve months in the trial (which is the designed follow-up duration).
Study Procedures: Implementation Research Framework
Data collection will be conducted using a standardized protocol across all clinical sites and will include the following components:
User Survey. The survey will incorporate the user version of the Mobile Application Rating Scale (uMARS) to evaluate app quality across key domains, including engagement, functionality, aesthetics, information quality, and subjective app quality.
Focus Groups with Users. These focus groups will explore participants' experiences with the application, perceived benefits and challenges, and their engagement with the interpersonal support sessions. Discussions will follow a semi-structured guide to ensure consistency while allowing exploration of site-specific issues.
Semi-Structured Interviews with Health Professionals. The interviews will explore professionals' perspectives on patient adoption and acceptability of the HIVE application and IPS sessions, as well as their views on the integration of the HIVE framework into routine NCD care.
HIVE Clinical Trial Evaluation questionnaire. A survey will be administered for completion to all medical professionals involved in the trial in order to evaluate their experience.
146 studies on the registry are indexed under Noncommunicable Diseases; 57 are open to participants now.
This study's planned enrollment of 260 is below the median of 478 across 97 interventional studies indexed under Noncommunicable Diseases.
Browse Noncommunicable Diseases studies →University of Nicosia is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligible chronic non-communicable diseases include: Diabetes mellitus, hypertension, dyslipidaemia, ischaemic heart disease, heart failure, lung cancer, colon cancer, breast cancer, cervical cancer, anal cancer, Kaposi's sarcoma, lymphoma, depression, and anxiety disorder.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive the HIVE intervention package, which aims to improve the integrated management of HIV and chronic non-communicable diseases (NCDs). The intervention combines three components: (1) a mobile health (mHealth) application supporting self-management through health information, symptom monitoring, medication and appointment reminders, and personalised guidance; (2) interpersonal support (IPS) to address psychosocial needs and promote mental well-being; and (3) tools and procedures to support the integration of NCD care within existing HIV healthcare services. The interventions will be implemented across participating clinical sites in Greece, Malta, Kenya, and Kazakhstan. Participants will be followed for 12 months to assess effectiveness and implementation outcomes.
Behavioral: HIVE Mobile Health Application · Behavioral: HIVE Interpersonal Support (IPS) · Behavioral: Integration of NCD Care Into HIV Clinics
A digital health intervention intended to support self-management, health literacy, patient engagement, and access to healthcare services.
A structured psychosocial intervention intended to strengthen social support, coping strategies, and engagement with care.
A healthcare delivery intervention involving integrated care tools, provider training, and improved coordination of NCD management within HIV services.
Change in Self-Management Capability Assessed Using the Appraisal of Self-Care Agency Scale-Revised (ASAS-R)
Self-management capability will be assessed using the Appraisal of Self-Care Agency Scale-Revised (ASAS-R), a validated questionnaire measuring an individual's perceived ability to engage in self-care activities. The primary outcome is the change in ASAS-R scores from baseline to 12 months following implementation of the HIVE interventions among people living with HIV and at least one chronic non-communicable disease.
Time frame: Baseline and Month 12
Self-efficacy in managing medications and treatments
Change in participants' self-reported confidence in managing medications and treatments for chronic conditions, assessed using the PROMIS Self-Efficacy for Managing Medications and Treatments measure.
Time frame: Baseline and Month 12
Change in Self-Efficacy for Managing Symptoms of Chronic Conditions
Change in participants' self-reported confidence in managing symptoms associated with chronic conditions, assessed using the PROMIS Self-Efficacy for Managing Symptoms measure.
Time frame: Baseline and Month 12
Change in Health-Related Quality of Life
Change in quality of life among participants living with HIV and at least one non-communicable disease, assessed using the World Health Organization Quality of Life HIV Brief questionnaire (WHOQOL-HIV BREF).
Time frame: Baseline and Month 12
Change in Awareness of Non-Communicable Diseases
Change in participants' awareness of their chronic non-communicable diseases, assessed using the Awareness of NCD Questionnaire.
Time frame: Baseline and Month 12
Change in Depressive Symptoms
Change in depressive symptom scores among participants receiving interpersonal support, measured using the Patient Health Questionnaire-9 (PHQ-9).
Time frame: Baseline and End of Interpersonal Support Intervention
Change in Anxiety Symptoms
Change in anxiety symptom scores among participants receiving interpersonal support, measured using the Generalized Anxiety Disorder-7 (GAD-7).
Time frame: Baseline and End of Interpersonal Support Intervention
HIVE Mobile Application Quality and Acceptability
Participant-reported quality and acceptability of the HIVE mobile health application, assessed using the User Version of the Mobile App Rating Scale (uMARS).
Time frame: Week 4, Month 4, and Month 12
No study locations are listed for this record.
Plan to share: Undecided — At this point an IPD sharing plan has not been decided by the clinical trial participating sites and consortium. We view no reason not to share anonymized data, but since it hasn't been formally discussed we opt to reply as Undecided. We can update the registration once a decision has been made.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 79 non-industry interventional studies with no phase under Noncommunicable Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 12 months is below that.
Counting every sponsor, half of 79 studies reached it within 17 months; a quarter within 7 and three quarters within 30.
Noncommunicable Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Nicosia